Schedule of Pharmaceutical Benefits - 1 June 2021

PBAC

1 June 2021 - The June 2021 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The June issue of the Schedule includes a few new/revised listings:

  • Adalimumab (Humira) - new strength
  • Beclomethasone dipropionate with eformoterol fumarate dihydrate and glycopyrronium bromide (Trimbow) - new combination product
  • Bevacizumab (Mvasi) - new biosimilar medicine
  • Galcanezumab (Emgality) - new medicine
  • High fat formula with vitamins, minerals and trace elements and low in protein and carbohydrate (KetoVie 3:1) - new formulation
  • High fat formula with vitamins, minerals and trace elements and low in protein and carbohydrate (KetoVie 4:1) - new formulation
  • Progesterone (Oripro) - new indication
  • Tenofovir disoproxil succinate with emtricitabine (Tenofovir/Emtricitabine Sandoz 301/200) - new formulation
  • Tolvaptan (Jinarc) - new strength

Read Summary of PBS changes

Michael Wonder

Posted by:

Michael Wonder